UNSPSC 51262604: Phentolamine

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C17H19N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z468598HBV, chemically known as 2-imidazoline, 2-((n-(m-hydroxyphenyl)-p-toluidino)methyl)- but generally known as phentolamine, which bears US NIH Compound Identifier 5775. European Medicines Agency schedules Phentolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09785MIG. The term PHENTOLAMINE is an International Non-Proprietary Name.

UNSPSC 51262604 Phentolamine is a Commodity code that covers pharmaceutical products used in emergency medical response and opioid-overdose intervention. State and local governments procure naloxone, drug deactivation systems, and related pharmaceutical supplies under this code to support public health initiatives, community health programs, and emergency medical services. Issuing bodies include county health departments and state health and human services agencies; Seminole County, Florida and the Texas Health and Human Services Commission appear in recent activity. The procurement spans both ongoing supply contracts for naloxone and emergency-response pharmaceuticals and exploratory market-intelligence activities around direct-to-manufacturer pharmacy procurement models.

Recent activity is concentrated in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (response due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the contract carries a two-year initial term with one-year renewal option and requires E-Verify compliance, drug-free workplace certification, and standard commercial insurance. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on vendors' experience with direct contracting for self-insured employers and health plans, negotiated net pricing models, and value-based outcomes agreements; no formal evaluation criteria or award values are specified at this exploratory stage. The source shows limited recent activity under the code and a mismatch between the nominal code name (phentolamine, a specific pharmaceutical) and the actual procurements being tagged to it (naloxone and drug deactivation systems).